Morgan Stanley Keeps Their Hold Rating on Abbott Laboratories (ABT)
Nephron Adjusts Price Target on Abbott Laboratories to $110 From $115
Maintained Buy Rating for Abbott Laboratories on Strong Financials and Growth Prospects
UBS Sticks to Its Hold Rating for US Bancorp (USB)
Buy Rating Affirmed on Abbott Laboratories Amid Strong Q2 Results and Raised 2024 Guidance
CIBC Adjusts Price Target on Weyerhaeuser to $34 From $37
Buy Rating Affirmed for Abbott Laboratories Amid Strong Financials and Growth Potential
U.S. Bancorp Analyst Ratings
RBC Capital Sticks to Their Buy Rating for US Bancorp (USB)
Buy Rating for US Bancorp on Strong Q2 Performance and Positive Outlook
DA Davidson Adjusts Price Target on U.S. Bancorp to $49 From $44, Maintains Neutral Rating
Exxon Mobil Analyst Ratings
Piper Sandler Raises Price Target on U.S. Bancorp to $47 From $43, Maintains Neutral Rating
Exxon Mobil (XOM) Receives a Buy From Morgan Stanley
Piper Sandler Sticks to Its Buy Rating for Exxon Mobil (XOM)
Weyerhaeuser Analyst Ratings
Truist Securities Maintains Hold on Medtronic, Lowers Price Target to $85
Medtronic Analyst Ratings
BNP Paribas Exane Adjusts Price Target on Comcast to $35 From $34
Truist Adjusts Weyerhaeuser's Price Target to $32 From $36